Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 45 for “"Pirfenidone"”.
-
Therapeutic use of pirfenidone against septic shock
… subsequent pathology. A new experimental drug, pirfenidone, (5-methyl-l-phenyl-2-(lH)-pyridone, trade name: Deskar) has been reported to have beneficial effects for the treatment of certain fibrotic diseases. The present study describes the use of pirfenidone, which inhibits both the release of …
-
Effects of Pirfenidone in a Mouse Liver Fibrosis Model
… few options available to combat fibrogenesis. Pirfenidone (Esbriet®) is an anti-fibrotic agent for treatment of idiopathic pulmonary fibrosis, which downregulates the production of growth factors and procollagens I and II and inhibits fibroblast proliferation. We aimed to test anti-fibrotic …
-
A pilot study: pirfenidone, 8% (KitosCell) as a treatment for striae distensae
… medical need may be addressed by the use of Pirfenidone. Pirfenidone is a small synthetic non-peptide molecule of low molecular weight (185.2 Daltons) that has been identified to have immuno-modulatory and anti-inflammatory properties. Clinical evidence indicates that Pirfenidone can modulate …
-
Effect of Anti-fibrotic Drug (Pirfenidone) on TGF-β Signaling Pathway in Ocular Fibrotic Disorders
… disorders of the retina. Herein, the effect of pirfenidone, a novel anti-fibrotic agent, on TGF-β1-mediated fibrogenesis in the human RPE cell line (ARPE)-19 was tested. Methods: The effect of pirfenidone on the TGF-β1-induced phenotype in ARPE-19 cells was measured with immunocytochemistry as …
-
Anti-fibrotic effects of Nintedanib and Pirfenidone on alveolar epithelial cell function in ex-vivo 3D-Lung Tissue Cultures
… to slow disease progression are Nintedanib and Pirfenidone. However, the life expectancy is still limited with or without treatment. Therefore, novel therapeutic options are needed. In this context, a more in- depth understanding of the mechanism of action of Nintedanib and Pirfenidone might …
-
Harnessing Exosomes from Human Dermal Fibroblasts and Pirfenidone-exosomes as Innovative Strategies for Scarless Tissue Repair in Wound Healing
… activity is a promising strategy, with pirfenidone (PFD) showing potential due to its anti-fibrotic properties by targeting intracellular pathways that regulate collagen disposition. PFD, particularly when delivered via dermal fibroblast-derived exosomes, may further enhance therapeutic …
-
Dry powder for inhalation of single and fixed dose combinations of nintedanib, pirfenidone and mycophenolic acid prepared by thin-film freezing technology
… inhaled fixed-dose combinations of nintedanib, pirfenidone and mycophenolic acid for idiopathic pulmonary fibrosis (IPF) to improve efficacy and safety over oral administration. In this study, we found that the TFF process achieved the challenges in producing inhaled fixed-dose combinations of …
-
Which factors predict early discontinuation of antifibrotics in idiopathic pulmonary fibrosis?
Introduction: Pirfenidone and nintedanib are recommended in idiopathic pulmonary fibrosis (IPF). Randomised controlled trials have shown discontinuation rates of 14-33%; clinical audit in our regional centre showed a rate of 18.4%. I aimed to establish the main factors, which predict early …
-
Biomarker discovery and drug testing in Idiopathic Pulmonary Fibrosis
… of mild-to-moderate IPF worldwide, neither Pirfenidone or Nintedanib provide a definitive cure for disease, but slow in disease progression. Thus, animal models of pulmonary fibrosis are a critical tool for disease understanding, drug development and pre-clinical intervention. In chapter …
-
LAYERED, FLEXIBLE DRUG DELIVERY FILMS FOR THE PREVENTION OF FIBROTIC SCAR TISSUE FORMATION
… were loaded with quercetin, an anti‐oxidant, or pirfenidone, an anti‐fibrotic, and plasticized with TEC or TBC. TEC‐plasticized films containing quercetin released drug at a slower rate than TBC films. Pirfenidone‐loaded films released drug at a faster rate than erosion occurred for both …
-
Exploring Collagen VI’s Influence on Cardiac Pathophysiology: Structural and Functional Insights in Health and Disease Summer Hassan Department of Physiology Faculty of Medical and Health Science University of Auckland, New Zealand A thesis
… agents, the thesis explored the effects of pirfenidone treatment on cardiac function by utilising MI-induced heart failure rat models treated with pirfenidone. Pirfenidone treatment reduced myocardial fibrosis and improved diastolic function. However, contrary to expectations, it promoted …
-
The Effect of Activated M1 Macrophages on Fibrotic Human Lung Microtissue Array
… HLF cells are treated with anti-fibrosis drug, Pirfenidone. Pirfenidone is taken at two different concentrations which shows how the drug negates the effect of M1 macrophages on HLF cells and also help control fibrosis.
-
Investigation of novel therapeutic strategies for attenuating corneal fibrosis
… and efficacy of two unique pharmacologic agents (Pirfenidone and Fasudil) with known antifibrotic effects in non-ocular organ systems for attenuating TGF[beta]-mediated corneal fibrosis in vitro and in vivo. We also evaluated the ability of nanoparticle-mediated combination gene therapy (PEI-GNP) …
-
Idiopathic pulmonary fibrosis: pathogenesis, progression, treatments, and future prospects
… and mortality rates of IPF still remain high. Pirfenidone, the other currently available pharmaceutical therapeutic, was discovered in 1976 as a potent inhibitor of inflammation. Subsequent experiments further reviled its potency as an anti-fibrotic drug. After decades of research, …
-
The Genetic Epidemiology of Complex Lung Diseases
… and uncover potential mechanisms by which pirfenidone and nintedanib attenuate fibrosis by performing an integrative ‘omics analysis of transcriptomics and proteomic responses to TGFb1-stimulated lung fibroblasts; 2) define a skeletal muscle fiber shift phenotype in both males and females …
-
The role of telomeres in pulmonary fibrosis and its effects on choices of treatment
… N-acetylcysteine, prednisone, azathioprine, pirfenidone, nintedanib (with and without statins), and low-dose inhaled carbon monoxide. The treatment options with the favored positive results are danazol and nintedanib.
-
Development Of An Ophthalmic Nanoemulsion Topical Formulation For Corneal Wound Healing
… to prevent inflammation, avoid the fibrosis. Pirfenidone (PFD) has recently been investigated for its anti-fibrotic effect. The current study was undertaken to develop and optimize PFD-loaded nanoemulsion (NE; PFD-NE) which could increase the drug load and the duration of activity. Hot …
Page 1 of 3